Nuage Therapeutics

Nuage Therapeutics is a biotechnology company developing a drug discovery platform to create therapies for cancers driven by intrinsically disordered proteins (IDPs). The company was founded in 2021 as a spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and ICREA. The founders include researchers Dr. Xavier Salvatella, Dr. Mateusz Biesaga, Dr. Denes Hnisz, and Dr. Judit Anido. Their scientific backgrounds are central to the company's technology, which is based on years of research into undruggable protein targets.

The company's proprietary technology leverages the phenomenon of biomolecular condensation, enabling a screening assay to identify drug-like small molecules that can modulate IDPs. These proteins lack a stable three-dimensional structure, making them difficult to target with conventional drug discovery methods. Nuage's approach captures these disordered proteins in a more structured form, making them amenable to small molecule screening and unlocking a range of previously intractable oncogenic transcription factors. The business model focuses on developing a pipeline of novel agents, with an initial focus on oncology. The company's lead program targets castration-resistant prostate cancer, the second-leading cause of cancer death in men. Revenue generation is anticipated through the development and subsequent commercialization or partnership of these therapies.

Nuage has secured significant funding to advance its research. In June 2023, the company raised €12 million in a seed round led by Sofinnova Partners and Asabys Partners, with participation from CDTI's Innvierte program and BStartup. This was followed by a €1.8 million capital injection in May 2025 from CDTI Innovación and Sofinnova Capital X to further its oncology therapy development. In March 2025, Dr. Stuart Hughes was appointed as the new CEO, succeeding founding CEO Dr. Judit Anido, to guide the company's next growth phase.

Keywords: intrinsically disordered proteins, IDP, drug discovery, cancer therapies, small molecules, oncology, castration-resistant prostate cancer, biomolecular condensates, undruggable targets, precision therapies, oncogenic transcription factors, biophysics, chemical biology, IRB Barcelona, spin-off, Sofinnova Partners, Asabys Partners, prostate cancer treatment, therapeutic agents, biotechnology